Literature DB >> 10595932

Expression of costimulatory molecules in low-grade mucosa-associated lymphoid tissue-type lymphomas in vivo.

C Knörr1, C Amrehn, H Seeberger, A Rosenwald, S Stilgenbauer, G Ott, H K Müller Hermelink, A Greiner.   

Abstract

B-cell lymphomas of mucosa-associated lymphoid tissue (MALT) type develop against a background of chronic inflammation and have functional autoantigen receptors. Because they respond to environmental factors in vivo, the expression of costimulatory molecules, which play a key role in the differentiation of normal B-lymphocytes and in T-/B-cell interaction, may be critical in early MALT-type lymphoma pathogenesis until further chromosomal aberration leads to progression. We found a high number of tumor-infiltrating T-lymphocytes (TITLs) in all low-grade MALT-type lymphomas. The TITLs in low-grade lymphomas were activated and expressed a memory and immunocompetent phenotype. Reverse transcriptase-polymerase chain reaction analyses and immunohistochemistry confirmed the presence of CD40-ligand and Fas-ligand in 80% of low-grade lymphomas. In contrast to the TITLs, the tumor B cells did not express CD40-ligand or Fas-ligand in vivo or in vitro. Moreover, the cytokine profile in vivo suggested a Th2/Th3-weighted profile (interleukin-10, interleukin-13, transforming growth factor beta(1)) rather than Th1-weighted (interferon-gamma, interleukin-2). By interphase fluorescence in situ hybridization analysis the translocation t(11;18)(q21;q21) was found in four of nine (44%) cases studied. Interestingly, there was a four times higher proliferation and survival rate of purified t(11;18)-positive tumor B cells in vitro, although there were no significant profile differences from the TITLs in vivo. The finding of essential costimulating molecules in low-grade MALT-type lymphomas in vivo indicates a locally directed cognate T-/B-cell interaction. Consequently, a potentially equipped inflammatory background may not only determine the fate of autoreactive B-cells, but is also crucial to lymphoma maintenance and progression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10595932      PMCID: PMC1866945          DOI: 10.1016/S0002-9440(10)65521-6

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  51 in total

1.  Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity.

Authors:  K Grønbaek; P T Straten; E Ralfkiaer; V Ahrenkiel; M K Andersen; N E Hansen; J Zeuthen; K Hou-Jensen; P Guldberg
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

2.  Mechanisms of antigen receptor-dependent apoptosis of human B lymphoma cells probed with a panel of 27 monoclonal antibodies.

Authors:  G Grafton; M Goodall; C D Gregory; J Gordon
Journal:  Cell Immunol       Date:  1997-11-25       Impact factor: 4.868

3.  Analysis of TH1 and TH2 cytokine production in low grade B cell gastric MALT-type lymphomas stimulated in vitro with Helicobacter pylori.

Authors:  A C Hauer; T M Finn; T T MacDonald; J Spencer; P G Isaacson
Journal:  J Clin Pathol       Date:  1997-11       Impact factor: 3.411

4.  The t(11;18)(q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin's lymphomas of the mucosa-associated lymphoid tissue (MALT-) type.

Authors:  G Ott; T Katzenberger; A Greiner; J Kalla; A Rosenwald; U Heinrich; M M Ott; H K Müller-Hermelink
Journal:  Cancer Res       Date:  1997-09-15       Impact factor: 12.701

5.  Primary hepatic low-grade B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) associated with primary biliary cirrhosis.

Authors:  R M Prabhu; L J Medeiros; D Kumar; C I Drachenberg; J C Papadimitriou; H D Appelman; L B Johnson; J Laurin; M Heyman; L V Abruzzo
Journal:  Mod Pathol       Date:  1998-04       Impact factor: 7.842

6.  Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis.

Authors:  J Plumas; M C Jacob; L Chaperot; J P Molens; J J Sotto; J C Bensa
Journal:  Blood       Date:  1998-04-15       Impact factor: 22.113

7.  TGF-beta1 alters APC preference, polarizing islet antigen responses toward a Th2 phenotype.

Authors:  C King; J Davies; R Mueller; M S Lee; T Krahl; B Yeung; E O'Connor; N Sarvetnick
Journal:  Immunity       Date:  1998-05       Impact factor: 31.745

8.  Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells.

Authors:  N Voorzanger-Rousselot; M Favrot; J Y Blay
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

9.  Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue.

Authors:  T Hussell; P G Isaacson; J E Crabtree; J Spencer
Journal:  J Pathol       Date:  1996-02       Impact factor: 7.996

10.  CD40 ligand and autoantigen are involved in the pathogenesis of low-grade B-cell lymphomas of mucosa-associated lymphoid tissue.

Authors:  A Greiner; C Knörr; Y Qin; A Schultz; A Marx; R A Kroczek; H K Müller-Hermelink
Journal:  Dev Immunol       Date:  1998
View more
  9 in total

1.  Expression of interleukin-4 and interleukin-13 and their receptors in colorectal cancer.

Authors:  Andrea Formentini; Philipp Braun; Harald Fricke; Karl-Heinrich Link; Doris Henne-Bruns; Marko Kornmann
Journal:  Int J Colorectal Dis       Date:  2012-03-24       Impact factor: 2.571

2.  Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the marginal zone B-cell transcription factor Notch2 in splenic marginal zone lymphoma.

Authors:  Gunhild Trøen; Vigdis Nygaard; Tor-Kristian Jenssen; Ida Münster Ikonomou; Anne Tierens; Estella Matutes; Alicja Gruszka-Westwood; Daniel Catovsky; Ola Myklebost; Grete Lauritzsen; Eivind Hovig; Jan Delabie
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

3.  The role of antigenic drive and tumor-infiltrating accessory cells in the pathogenesis of helicobacter-induced mucosa-associated lymphoid tissue lymphoma.

Authors:  Anne Mueller; Jani O'rourke; Pauline Chu; Amanda Chu; Michael F Dixon; Donna M Bouley; Adrian Lee; Stanley Falkow
Journal:  Am J Pathol       Date:  2005-09       Impact factor: 4.307

4.  Tumor-infiltrating T cells with similar antigen binding sites in different mucosa-associated lymphoid tissue type B cell lymphomas.

Authors:  Harald Seeberger; Constanze Knörr; Christian Mainhardt; Hans Konrad Müller-Hermelink; Axel Greiner
Journal:  Virchows Arch       Date:  2003-02-19       Impact factor: 4.064

5.  Detection of two cell populations corresponding to distinct maturation stages in API-2/MLT-positive mucosa-associated lymphoid tissue lymphoma cells proliferating in pleural effusion.

Authors:  Yuya Kunisaki; Tsuyoshi Muta; Yujiro Yamano; Yukio Kobayashi
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

Review 6.  Helicobacter pylori and gastric mucosa-associated lymphoid tissue lymphoma: recent progress in pathogenesis and management.

Authors:  Shotaro Nakamura; Takayuki Matsumoto
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

7.  Interferon-γ promotes gastric lymphoid follicle formation but not gastritis in Helicobacter-infected BALB/c mice.

Authors:  Michelle Chonwerawong; Patrick Avé; Michel Huerre; Richard L Ferrero
Journal:  Gut Pathog       Date:  2016-11-21       Impact factor: 4.181

8.  The local immune response of mice after Helicobacter suis infection: strain differences and distinction with Helicobacter pylori.

Authors:  Bram Flahou; Kim Van Deun; Frank Pasmans; Annemieke Smet; Jiri Volf; Ivan Rychlik; Richard Ducatelle; Freddy Haesebrouck
Journal:  Vet Res       Date:  2012-10-29       Impact factor: 3.683

9.  Diversity in bacterium-host interactions within the species Helicobacter heilmannii sensu stricto.

Authors:  Myrthe Joosten; Caroline Blaecher; Bram Flahou; Richard Ducatelle; Freddy Haesebrouck; Annemieke Smet
Journal:  Vet Res       Date:  2013-07-29       Impact factor: 3.683

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.